Iovance Biotherapeutics, Inc. (IOVA)
Oxford Ledge is still expanding full research coverage of IOVA. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Iovance develops individualized T cell therapies for solid tumors, with its lead product Amtagvi approved for advanced melanoma in the U.S. and Canada.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-07-02
- 8-K Shareholder vote results; Other material event; Financial statements and exhibits 2026-06-10
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-07
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- DEF 14A Proxy statement for shareholder vote 2026-04-28
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for IOVA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open IOVA in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.